<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathogens</journal-id><journal-id journal-id-type="iso-abbrev">Pathogens</journal-id><journal-id journal-id-type="publisher-id">pathogens</journal-id><journal-title-group><journal-title>Pathogens</journal-title></journal-title-group><issn pub-type="epub">2076-0817</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3390/pathogens9020109</article-id><article-id pub-id-type="publisher-id">pathogens-09-00109</article-id><article-categories><subj-group subj-group-type="heading"><subject>Opinion</subject></subj-group></article-categories><title-group><article-title>Human Metapneumovirus: A Largely Unrecognized Threat to Human Health</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Russell</surname><given-names>Charles J.</given-names></name><xref ref-type="aff" rid="af1-pathogens-09-00109">1</xref><xref ref-type="aff" rid="af2-pathogens-09-00109">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5317-1055</contrib-id><name><surname>Penkert</surname><given-names>Rhiannon R.</given-names></name><xref ref-type="aff" rid="af1-pathogens-09-00109">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sonnie</given-names></name><xref ref-type="aff" rid="af3-pathogens-09-00109">3</xref></contrib><contrib contrib-type="author"><name><surname>Hurwitz</surname><given-names>Julia L.</given-names></name><xref ref-type="aff" rid="af1-pathogens-09-00109">1</xref><xref ref-type="aff" rid="af2-pathogens-09-00109">2</xref><xref rid="c1-pathogens-09-00109" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pathogens-09-00109"><label>1</label>Department of Infectious Diseases, St. Jude Children&#x02019;s Research Hospital, Memphis, TN 38105, USA; <email>charles.russell@stjude.org</email> (C.J.R.); <email>rhiannon.penkert@stjude.org</email> (R.R.P.)</aff><aff id="af2-pathogens-09-00109"><label>2</label>Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA</aff><aff id="af3-pathogens-09-00109"><label>3</label>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA; <email>sonnie.kim@nih.gov</email></aff><author-notes><corresp id="c1-pathogens-09-00109"><label>*</label>Correspondence: <email>julia.hurwitz@stjude.org</email>; Tel.: +1-901-595-2464</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2020</year></pub-date><volume>9</volume><issue>2</issue><elocation-id>109</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Human metapneumovirus (HMPV) infects most children by five years of age. The virus can cause both upper and lower respiratory tract disease and can be life threatening. High-risk populations include young children who are exposed to virus for the first time and the elderly. Currently, there is no standard treatment nor licensed vaccine for HMPV, although several attractive vaccine candidates have been developed for pre-clinical studies. A raised awareness of the impact of HMPV on public health is needed to drive research, complete vaccine development, and thereby prevent significant virus-associated morbidities and mortalities worldwide.</p></abstract><kwd-group><kwd>respiratory virus infection</kwd><kwd>Sendai virus</kwd><kwd>vaccine development</kwd></kwd-group></article-meta></front><body><sec id="sec1-pathogens-09-00109"><title>1. The Virus</title><p>Human metapneumovirus (HMPV) is a negative-strand RNA virus that replicates in the cytoplasm [<xref rid="B1-pathogens-09-00109" ref-type="bibr">1</xref>]. HMPV and avian metapneumovirus (AMPV), the closest known relative of HMPV, are members of the genus <italic>Metapneumovirus</italic> and the family <italic>Pneumoviridae</italic> [<xref rid="B2-pathogens-09-00109" ref-type="bibr">2</xref>]. HMPV shares many features with respiratory syncytial virus (RSV) of the genus <italic>Orthopneumovirus</italic> and family <italic>Pneumoviridae</italic> [<xref rid="B3-pathogens-09-00109" ref-type="bibr">3</xref>]. The HMPV genome is approximately 13,000 nucleotides in length. HMPV virions contain a ribonucleocapsid core consisting of viral RNA (vRNA), nucleocapsid (N) protein, polymerase (L) protein, phosphoprotein (P), and M2-1 protein [<xref rid="B4-pathogens-09-00109" ref-type="bibr">4</xref>]. The matrix (M) protein lines the inner face of the virion envelope. Envelope spikes projecting from the virus include a small hydrophobic (SH) protein and the attachment (G) and fusion (F) glycoproteins. An M2-2 protein regulates RNA synthesis and supports virus growth in a hamster model [<xref rid="B5-pathogens-09-00109" ref-type="bibr">5</xref>]. HMPV exists as filaments and spherical particles with diameters that range from 150 to 600 nm [<xref rid="B1-pathogens-09-00109" ref-type="bibr">1</xref>]. It appears morphologically similar to RSV and to members of the family <italic>Paramyxoviridae</italic>. In fact, HMPV and RSV were previously classified as members of the <italic>Paramyxoviridae</italic> family; listings were recently changed by the International Committee on Taxonomy of Viruses (ICTV) [<xref rid="B6-pathogens-09-00109" ref-type="bibr">6</xref>]. </p><p>HMPV envelope glycoproteins include the G and F proteins. The open reading frame (ORF) of G encodes a 229&#x02013;236 residue glycoprotein that is unrelated in nucleotide or amino acid sequence to other pneumovirus or paramyxovirus G proteins [<xref rid="B4-pathogens-09-00109" ref-type="bibr">4</xref>]. The G protein binds heparan sulfate and other glycosaminoglycans found on airway epithelial cells in nasal and lung tissues to initiate viral entry [<xref rid="B7-pathogens-09-00109" ref-type="bibr">7</xref>,<xref rid="B8-pathogens-09-00109" ref-type="bibr">8</xref>]. </p><p>The ORF of F encodes a 539 residue glycoprotein that shares 33%&#x02013;38% amino acid identity with other pneumovirus F proteins and 10%&#x02013;18% identity with paramyxovirus F proteins [<xref rid="B4-pathogens-09-00109" ref-type="bibr">4</xref>]. As is the case for other pneumoviruses and paramyxoviruses, the F protein is synthesized as an F0 precursor protein that is subsequently cleaved into fusion-capable F1 and F2 subunits that form a large, trimeric, mushroom-like extracellular head in addition to C-terminal transmembrane (TM) and cytoplasmic tail regions. High-resolution structures have been obtained for the HMPV F protein ectodomain in both prefusion and postfusion forms [<xref rid="B9-pathogens-09-00109" ref-type="bibr">9</xref>,<xref rid="B10-pathogens-09-00109" ref-type="bibr">10</xref>]. These structures share many structural features common to prefusion and postfusion forms of the F proteins from RSV and paramyxoviruses [<xref rid="B11-pathogens-09-00109" ref-type="bibr">11</xref>,<xref rid="B12-pathogens-09-00109" ref-type="bibr">12</xref>,<xref rid="B13-pathogens-09-00109" ref-type="bibr">13</xref>,<xref rid="B14-pathogens-09-00109" ref-type="bibr">14</xref>]. After receptor binding, the F protein undergoes a dramatic change in structure that causes membrane fusion to allow virus entry. Most strains of HMPV catalyze membrane fusion at neutral pH [<xref rid="B15-pathogens-09-00109" ref-type="bibr">15</xref>] while others are triggered by low pH in endosomes [<xref rid="B16-pathogens-09-00109" ref-type="bibr">16</xref>,<xref rid="B17-pathogens-09-00109" ref-type="bibr">17</xref>]. In addition to membrane fusion, the F protein can also facilitate receptor binding through an Arg-Gly-Asp (RGD) motif that binds integrins [<xref rid="B18-pathogens-09-00109" ref-type="bibr">18</xref>,<xref rid="B19-pathogens-09-00109" ref-type="bibr">19</xref>]. </p></sec><sec id="sec2-pathogens-09-00109"><title>2. HMPV Discovery, Diagnoses, and Prevalence</title><p>HMPV was discovered in 2001 after isolation from dozens of young children in the Netherlands [<xref rid="B1-pathogens-09-00109" ref-type="bibr">1</xref>]. Soon after its initial identification, HMPV was found globally as an etiological agent of respiratory infections in young children and elderly adults [<xref rid="B20-pathogens-09-00109" ref-type="bibr">20</xref>,<xref rid="B21-pathogens-09-00109" ref-type="bibr">21</xref>,<xref rid="B22-pathogens-09-00109" ref-type="bibr">22</xref>,<xref rid="B23-pathogens-09-00109" ref-type="bibr">23</xref>]. In temperate climates, HMPV epidemics tend to occur in winter and spring while in tropical climates, they are more sporadic [<xref rid="B24-pathogens-09-00109" ref-type="bibr">24</xref>,<xref rid="B25-pathogens-09-00109" ref-type="bibr">25</xref>,<xref rid="B26-pathogens-09-00109" ref-type="bibr">26</xref>,<xref rid="B27-pathogens-09-00109" ref-type="bibr">27</xref>,<xref rid="B28-pathogens-09-00109" ref-type="bibr">28</xref>].</p><p>Polymerase chain reaction (PCR) assays and immunofluorescence assays are often used to diagnose HMPV [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. These assays can score the viral nucleic acids and proteins of an acute infection and they may also score residual viral components after replication-competent virus has been cleared. Serum anti-viral antibodies serve as another marker of HMPV exposure, because the B cell response to HMPV is rapid and long-lasting [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. Serological findings suggest HMPV has been circulating globally in humans for decades or more before its first discovery, and that most children are first infected with HMPV before the age of five [<xref rid="B31-pathogens-09-00109" ref-type="bibr">31</xref>,<xref rid="B32-pathogens-09-00109" ref-type="bibr">32</xref>,<xref rid="B33-pathogens-09-00109" ref-type="bibr">33</xref>], with nearly 100% of teenagers and adults being seropositive [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B34-pathogens-09-00109" ref-type="bibr">34</xref>]. The late discovery of HMPV was likely due to the virus&#x02019;s slow replication, requirement for trypsin, and minimal cytopathic effects (CPE) in many tissue culture cell lines. HMPV disease was often attributed to another virus such as RSV or influenza. Tertiary monkey kidney epithelial cells were eventually found to support robust HMPV amplification and CPE [<xref rid="B1-pathogens-09-00109" ref-type="bibr">1</xref>]. </p></sec><sec id="sec3-pathogens-09-00109"><title>3. The Disease and Risk Factors</title><p>Following HMPV exposure, an innate cell, B cell, and T cell immune response usually develops within days and assists rapid virus clearance [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. However, HMPV can cause both upper respiratory tract (URT) and lower respiratory tract (LRT) disease, in some cases exacerbated by immune function [<xref rid="B35-pathogens-09-00109" ref-type="bibr">35</xref>,<xref rid="B36-pathogens-09-00109" ref-type="bibr">36</xref>]. LRT disease can be severe, particularly when an individual is exposed to virus for the first time. Outcomes can include bronchiolitis and pneumonia and can result in death [<xref rid="B37-pathogens-09-00109" ref-type="bibr">37</xref>]. </p><p>Among numerous studies of hospitalized and outpatient children worldwide, HMPV has been associated with between 6% and 40% of respiratory illnesses [<xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. A study by Edwards et al. in the United States estimated that HMPV was responsible for annual hospitalization rates of approximately 1 per 1000 children under the age of five [<xref rid="B33-pathogens-09-00109" ref-type="bibr">33</xref>]. In a study by Davis et al. in the United States, hospitalizations were highest for children under the age of 2 years (approximately 2 per 1000 person years). More than 50% of all hospitalized children had an underlying complex chronic condition such as a pulmonary disorder [<xref rid="B38-pathogens-09-00109" ref-type="bibr">38</xref>,<xref rid="B39-pathogens-09-00109" ref-type="bibr">39</xref>]; 18% required intensive care and 6% required mechanical ventilation. In a recent study in Norway described by Moe et al. [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B40-pathogens-09-00109" ref-type="bibr">40</xref>], up to 10% of children hospitalized with LRT disease were diagnosed with HMPV. In this study, the most severe symptoms were observed among children between the ages of 1 and 2 years, indicating that maternal antibodies provided a degree of protection to infants. Risk factors for serious disease included a history of premature birth or chronic airway disease. A history of premature birth was similarly identified as a risk factor for severe HMPV disease by Pancham et al. in their study of pre-school children [<xref rid="B41-pathogens-09-00109" ref-type="bibr">41</xref>,<xref rid="B42-pathogens-09-00109" ref-type="bibr">42</xref>].</p><p>Re-infections with HMPV are common, albeit usually mild. The virus threat increases when the human immune system is weakened, as in the context of hematopoietic stem cell transplantation. Aged individuals comprise another vulnerable population due to their waning immune function [<xref rid="B36-pathogens-09-00109" ref-type="bibr">36</xref>,<xref rid="B43-pathogens-09-00109" ref-type="bibr">43</xref>,<xref rid="B44-pathogens-09-00109" ref-type="bibr">44</xref>,<xref rid="B45-pathogens-09-00109" ref-type="bibr">45</xref>].</p></sec><sec id="sec4-pathogens-09-00109"><title>4. Treatment and Drug Discovery Efforts </title><p>There are no standard treatments for HMPV except supportive care. Ribavirin, a nucleoside analogue, has exhibited anti-HMPV activity in laboratory studies, but its use in clinical studies has yielded conflicting results [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B46-pathogens-09-00109" ref-type="bibr">46</xref>,<xref rid="B47-pathogens-09-00109" ref-type="bibr">47</xref>]. The efficacy, route of administration, and dosing of ribavirin for treatments of respiratory infections have been topics of continuous debate [<xref rid="B48-pathogens-09-00109" ref-type="bibr">48</xref>]. Other therapies are being developed to block HMPV fusion. For example, the peptide HRA2 (derived from a heptad repeat domain of the HMPV F protein) was shown to significantly reduce viral loads in animal studies [<xref rid="B49-pathogens-09-00109" ref-type="bibr">49</xref>]. Additionally, small interfering RNAs have been used to block HMPV infections [<xref rid="B50-pathogens-09-00109" ref-type="bibr">50</xref>,<xref rid="B51-pathogens-09-00109" ref-type="bibr">51</xref>]. Intravenous immune globulin (IVIG) or HMPV-specific monoclonal antibodies could potentially be used to neutralize HMPV [<xref rid="B52-pathogens-09-00109" ref-type="bibr">52</xref>], but their benefits as treatment options for HMPV disease have not been proven. For RSV, virus-specific antibodies have been successful as prophylaxes (particularly for vulnerable children including premature infants and infants with heart/lung disease), but not as treatment [<xref rid="B53-pathogens-09-00109" ref-type="bibr">53</xref>,<xref rid="B54-pathogens-09-00109" ref-type="bibr">54</xref>,<xref rid="B55-pathogens-09-00109" ref-type="bibr">55</xref>]. To increase the number of treatment options, methods are now being developed to expedite the screening of anti-HMPV drug candidates [<xref rid="B56-pathogens-09-00109" ref-type="bibr">56</xref>]. Ongoing studies of HMPV protein structure/function will also assist future drug and vaccine development [<xref rid="B57-pathogens-09-00109" ref-type="bibr">57</xref>,<xref rid="B58-pathogens-09-00109" ref-type="bibr">58</xref>].</p></sec><sec id="sec5-pathogens-09-00109"><title>5. Vaccine Development </title><p>Vaccination is the most effective method for control of infectious diseases. If the immune system is primed before a virus exposure, it can eliminate virus in the URT and avoid trafficking of virus to the lung where the greatest damage is caused. </p><p>Several HMPV vaccines have been produced and tested in pre-clinical studies [<xref rid="B29-pathogens-09-00109" ref-type="bibr">29</xref>,<xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. These include recombinant vaccines such as vaccines based on alpha virus or bovine PIV3 [<xref rid="B59-pathogens-09-00109" ref-type="bibr">59</xref>,<xref rid="B60-pathogens-09-00109" ref-type="bibr">60</xref>,<xref rid="B61-pathogens-09-00109" ref-type="bibr">61</xref>]. Killed virus has been tested, although there is a concern that killed virus may exacerbate disease, as was the case in the 1960s when a formalin-inactivated RSV vaccine was clinically tested [<xref rid="B62-pathogens-09-00109" ref-type="bibr">62</xref>]. Protein, peptide, and virus like particle (VLP) vaccines have also been tried. Live-attenuated HMPV vaccines have been produced, including cold-adapted variants and viruses with mutations in the F or polymerase proteins [<xref rid="B30-pathogens-09-00109" ref-type="bibr">30</xref>]. </p><p>The HMPV surface glycoproteins G and F have both been tested as vaccine antigens. When F and G genes were individually expressed in recombinant human parainfluenza virus-type 1 (hPIV-1) constructs and tested in hamsters, the F construct exhibited better immunogenicity [<xref rid="B63-pathogens-09-00109" ref-type="bibr">63</xref>]. In a separate study, when a soluble G protein was expressed (ectodomain without transmembrane domain or cytoplasmic tail), it did not elicit neutralizing antibodies or protection from challenge in cotton rats [<xref rid="B64-pathogens-09-00109" ref-type="bibr">64</xref>]. In contrast, HMPV F vaccines have been produced using a variety of different vector systems and have repeatedly generated protective immune responses in preclinical animal models [<xref rid="B59-pathogens-09-00109" ref-type="bibr">59</xref>,<xref rid="B60-pathogens-09-00109" ref-type="bibr">60</xref>,<xref rid="B61-pathogens-09-00109" ref-type="bibr">61</xref>].</p><p>Sendai virus (SeV) was recently tested as a candidate vector for an HMPV F vaccine [<xref rid="B65-pathogens-09-00109" ref-type="bibr">65</xref>]. SeV is a mouse parainfluenza virus, closely related to hPIV-1. The recombinant was produced by inserting the HMPV F gene into the SeV backbone between F and HN genes. When the vaccine was delivered intranasally to small research animals, it induced a robust immune response that was protective against an HMPV challenge.</p><p>HMPV vaccines have rarely progressed to clinical studies, although a live-attenuated vaccine was once tested in adults [<xref rid="B66-pathogens-09-00109" ref-type="bibr">66</xref>]. For any new vaccine program, there are numerous steps required to advance from vaccine concept to clinical application. Steps typically include, but are not limited to: (i) vaccine design, (ii) pre-clinical vaccine testing for immunogenicity and efficacy in small and/or large animal models, (iii) preparation of pilot vaccine lots, (iv) stability testing, (v) toxicology testing, (vi) application to institutional and government regulatory boards for approval of vaccines produced with Good Manufacturing Practices (GMP) and associated clinical protocols, (vii) clinical testing of vaccines (phases I, II, III) with regulatory oversight, (viii) license application and approval, (ix) vaccine distribution to the target population using appropriate transport and storage conditions, (x) public acceptance and vaccine use, and (xi) continued vaccine monitoring for safety and efficacy. Lagging development of HMPV vaccines may be due, at least in part, to prioritization of other respiratory virus vaccine programs (e.g., influenza virus, RSV, coronavirus). </p></sec><sec id="sec6-pathogens-09-00109"><title>6. Raising Awareness</title><p>The threat of HMPV infection and disease continues unabated, perhaps because it is not fully recognized. When a respiratory viral infection occurs, it is often assumed to be due to an influenza virus infection and termed &#x02018;flu&#x02019;. Diagnostics may be available to score influenza virus and possibly RSV, but not HMPV. New multiplex assays that include HMPV are cost prohibitive in many hospitals. Therefore, diseases caused by HMPV will go undiagnosed and unreported. Here, we recommend that efforts be increased in the HMPV field to: <list list-type="bullet"><list-item><p>Advance research efforts to reveal mechanisms by which virus induces a host immune response.</p></list-item><list-item><p>Improve surveillance to measure the burden of HMPV disease.</p></list-item><list-item><p>Improve HMPV awareness among clinicians and patients.</p></list-item><list-item><p>Develop a low-cost diagnostic assay for HMPV.</p></list-item><list-item><p>Develop new drugs and treatment options for HMPV.</p></list-item><list-item><p>Advance HMPV vaccines through clinical trials and licensure.</p></list-item></list></p><p>The dedication of new funds and efforts to the conduct of vaccine clinical trials might provide the greatest benefit to the HMPV field by escorting vaccine candidates beyond the stage of pre-clinical testing. A licensed, efficacious vaccine against HMPV could then prevent a substantial number of hospitalizations among children and adults worldwide.</p></sec></body><back><notes><title>Author Contributions</title><p>Writing&#x02014;original draft preparation, J.L.H.; writing&#x02014;review and editing, C.J.R., R.R.P., S.K. and J.L.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>The writing of this manuscript was supported in part by ALSAC and grant NIH NCI P30-CA21765.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Charles J. Russell and Julia L. Hurwitz are authors on a patent describing Sendai virus.</p></notes><glossary><title>Abbreviations</title><p>Human metapneumovirus, HMPV; respiratory syncytial virus, RSV; parainfluenza virus type 3, PIV-3; Sendai virus, SeV; cytopathic effects, CPE; fusion protein, F; attachment glycoprotein, G; good manufacturing practices, GMP.</p></glossary><ref-list><title>References</title><ref id="B1-pathogens-09-00109"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hoogen</surname><given-names>B.G.</given-names></name><name><surname>de Jong</surname><given-names>J.C.</given-names></name><name><surname>Groen</surname><given-names>J.</given-names></name><name><surname>Kuiken</surname><given-names>T.</given-names></name><name><surname>de Groot</surname><given-names>R.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>A newly discovered human pneumovirus isolated from young children with respiratory tract disease</article-title><source>Nat. Med.</source><year>2001</year><volume>7</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/89098</pub-id><?supplied-pmid 11385510?><pub-id pub-id-type="pmid">11385510</pub-id></element-citation></ref><ref id="B2-pathogens-09-00109"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amarasinghe</surname><given-names>G.K.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Basler</surname><given-names>C.F.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name><name><surname>Beer</surname><given-names>M.</given-names></name><name><surname>Bejerman</surname><given-names>N.</given-names></name><name><surname>Blasdell</surname><given-names>K.R.</given-names></name><name><surname>Bochnowski</surname><given-names>A.</given-names></name><name><surname>Briese</surname><given-names>T.</given-names></name><name><surname>Bukreyev</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Taxonomy of the order Mononegavirales: Update 2017</article-title><source>Arch. Virol.</source><year>2017</year><volume>162</volume><fpage>2493</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1007/s00705-017-3311-7</pub-id><?supplied-pmid 28389807?><pub-id pub-id-type="pmid">28389807</pub-id></element-citation></ref><ref id="B3-pathogens-09-00109"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Karron</surname><given-names>R.A.</given-names></name></person-group><article-title>Respiratory syncytial virus and metapneumovirus</article-title><source>Fields Virology</source><edition>6th ed.</edition><person-group person-group-type="editor"><name><surname>Knipe</surname><given-names>D.M.</given-names></name><name><surname>Howley</surname><given-names>P.M.</given-names></name></person-group><publisher-name>Wolters Kluwer Health Adis (ESP)</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2013</year><volume>Volume 1</volume><fpage>1086</fpage></element-citation></ref><ref id="B4-pathogens-09-00109"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hoogen</surname><given-names>B.G.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Analysis of the genomic sequence of a human metapneumovirus</article-title><source>Virology</source><year>2002</year><volume>295</volume><fpage>119</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1355</pub-id><?supplied-pmid 12033771?><pub-id pub-id-type="pmid">12033771</pub-id></element-citation></ref><ref id="B5-pathogens-09-00109"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Biacchesi</surname><given-names>S.</given-names></name><name><surname>Pham</surname><given-names>Q.N.</given-names></name><name><surname>Tran</surname><given-names>K.C.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Luongo</surname><given-names>C.L.</given-names></name><name><surname>Skiadopoulos</surname><given-names>M.H.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name></person-group><article-title>Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: Effects on RNA synthesis, attenuation, and immunogenicity</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>6588</fpage><lpage>6597</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.11.6588-6597.2005</pub-id><pub-id pub-id-type="pmid">15890897</pub-id></element-citation></ref><ref id="B6-pathogens-09-00109"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonso</surname><given-names>C.L.</given-names></name><name><surname>Amarasinghe</surname><given-names>G.K.</given-names></name><name><surname>Banyai</surname><given-names>K.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Basler</surname><given-names>C.F.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name><name><surname>Bejerman</surname><given-names>N.</given-names></name><name><surname>Blasdell</surname><given-names>K.R.</given-names></name><name><surname>Briand</surname><given-names>F.X.</given-names></name><name><surname>Briese</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Taxonomy of the order Mononegavirales: Update 2016</article-title><source>Arch. Virol.</source><year>2016</year><volume>161</volume><fpage>2351</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1007/s00705-016-2880-1</pub-id><pub-id pub-id-type="pmid">27216929</pub-id></element-citation></ref><ref id="B7-pathogens-09-00109"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamson</surname><given-names>P.</given-names></name><name><surname>Thammawat</surname><given-names>S.</given-names></name><name><surname>Muchondo</surname><given-names>G.</given-names></name><name><surname>Sadlon</surname><given-names>T.</given-names></name><name><surname>Gordon</surname><given-names>D.</given-names></name></person-group><article-title>Diversity in glycosaminoglycan binding amongst HMPV G protein lineages</article-title><source>Viruses</source><year>2012</year><volume>4</volume><elocation-id>3785</elocation-id><pub-id pub-id-type="doi">10.3390/v4123785</pub-id><pub-id pub-id-type="pmid">23242371</pub-id></element-citation></ref><ref id="B8-pathogens-09-00109"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thammawat</surname><given-names>S.</given-names></name><name><surname>Sadlon</surname><given-names>T.A.</given-names></name><name><surname>Hallsworth</surname><given-names>P.G.</given-names></name><name><surname>Gordon</surname><given-names>D.L.</given-names></name></person-group><article-title>Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>11767</fpage><lpage>11774</lpage><pub-id pub-id-type="doi">10.1128/JVI.01208-08</pub-id><pub-id pub-id-type="pmid">18786997</pub-id></element-citation></ref><ref id="B9-pathogens-09-00109"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battles</surname><given-names>M.B.</given-names></name><name><surname>Mas</surname><given-names>V.</given-names></name><name><surname>Olmedillas</surname><given-names>E.</given-names></name><name><surname>Cano</surname><given-names>O.</given-names></name><name><surname>Vazquez</surname><given-names>M.</given-names></name><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>Melero</surname><given-names>J.A.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1528</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01708-9</pub-id><pub-id pub-id-type="pmid">29142300</pub-id></element-citation></ref><ref id="B10-pathogens-09-00109"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Krause</surname><given-names>J.C.</given-names></name><name><surname>Leser</surname><given-names>G.P.</given-names></name><name><surname>Cox</surname><given-names>R.G.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name><name><surname>Crowe</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name><surname>Jardetzky</surname><given-names>T.S.</given-names></name></person-group><article-title>Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site</article-title><source>Nat. Struct. Mol. Biol.</source><year>2012</year><volume>19</volume><fpage>461</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2250</pub-id><pub-id pub-id-type="pmid">22388735</pub-id></element-citation></ref><ref id="B11-pathogens-09-00109"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Leung</surname><given-names>S.</given-names></name><name><surname>Graepel</surname><given-names>K.W.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Baxa</surname><given-names>U.</given-names></name><name><surname>Yasuda</surname><given-names>E.</given-names></name><name><surname>Beaumont</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>1113</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1126/science.1234914</pub-id><pub-id pub-id-type="pmid">23618766</pub-id></element-citation></ref><ref id="B12-pathogens-09-00109"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>Kwong</surname><given-names>P.D.</given-names></name></person-group><article-title>Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>7788</fpage><lpage>7796</lpage><pub-id pub-id-type="doi">10.1128/JVI.00555-11</pub-id><?supplied-pmid 21613394?><pub-id pub-id-type="pmid">21613394</pub-id></element-citation></ref><ref id="B13-pathogens-09-00109"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.S.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Paterson</surname><given-names>R.G.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name><name><surname>Jardetzky</surname><given-names>T.S.</given-names></name></person-group><article-title>Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation</article-title><source>Nature</source><year>2006</year><volume>439</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nature04322</pub-id><?supplied-pmid 16397490?><pub-id pub-id-type="pmid">16397490</pub-id></element-citation></ref><ref id="B14-pathogens-09-00109"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.S.</given-names></name><name><surname>Paterson</surname><given-names>R.G.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Lamb</surname><given-names>R.A.</given-names></name><name><surname>Jardetzky</surname><given-names>T.S.</given-names></name></person-group><article-title>Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>9288</fpage><lpage>9293</lpage><pub-id pub-id-type="doi">10.1073/pnas.0503989102</pub-id><?supplied-pmid 15964978?><pub-id pub-id-type="pmid">15964978</pub-id></element-citation></ref><ref id="B15-pathogens-09-00109"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herfst</surname><given-names>S.</given-names></name><name><surname>Mas</surname><given-names>V.</given-names></name><name><surname>Ver</surname><given-names>L.S.</given-names></name><name><surname>Wierda</surname><given-names>R.J.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name><name><surname>Melero</surname><given-names>J.A.</given-names></name></person-group><article-title>Low-pH-induced membrane fusion mediated by human metapneumovirus F protein is a rare, strain-dependent phenomenon</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>8891</fpage><lpage>8895</lpage><pub-id pub-id-type="doi">10.1128/JVI.00472-08</pub-id><pub-id pub-id-type="pmid">18596097</pub-id></element-citation></ref><ref id="B16-pathogens-09-00109"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>R.G.</given-names></name><name><surname>Mainou</surname><given-names>B.A.</given-names></name><name><surname>Johnson</surname><given-names>M.</given-names></name><name><surname>Hastings</surname><given-names>A.K.</given-names></name><name><surname>Schuster</surname><given-names>J.E.</given-names></name><name><surname>Dermody</surname><given-names>T.S.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name></person-group><article-title>Human Metapneumovirus Is Capable of Entering Cells by Fusion with Endosomal Membranes</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005303</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005303</pub-id><pub-id pub-id-type="pmid">26629703</pub-id></element-citation></ref><ref id="B17-pathogens-09-00109"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schowalter</surname><given-names>R.M.</given-names></name><name><surname>Smith</surname><given-names>S.E.</given-names></name><name><surname>Dutch</surname><given-names>R.E.</given-names></name></person-group><article-title>Characterization of human metapneumovirus F protein-promoted membrane fusion: Critical roles for proteolytic processing and low pH</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>10931</fpage><lpage>10941</lpage><pub-id pub-id-type="doi">10.1128/JVI.01287-06</pub-id><pub-id pub-id-type="pmid">16971452</pub-id></element-citation></ref><ref id="B18-pathogens-09-00109"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cseke</surname><given-names>G.</given-names></name><name><surname>Maginnis</surname><given-names>M.S.</given-names></name><name><surname>Cox</surname><given-names>R.G.</given-names></name><name><surname>Tollefson</surname><given-names>S.J.</given-names></name><name><surname>Podsiad</surname><given-names>A.B.</given-names></name><name><surname>Wright</surname><given-names>D.W.</given-names></name><name><surname>Dermody</surname><given-names>T.S.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name></person-group><article-title>Integrin alphavbeta1 promotes infection by human metapneumovirus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>1566</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1073/pnas.0801433106</pub-id><pub-id pub-id-type="pmid">19164533</pub-id></element-citation></ref><ref id="B19-pathogens-09-00109"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>A.</given-names></name><name><surname>Masante</surname><given-names>C.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Dutch</surname><given-names>R.E.</given-names></name></person-group><article-title>Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>3230</fpage><lpage>3243</lpage><pub-id pub-id-type="doi">10.1128/JVI.06706-11</pub-id><pub-id pub-id-type="pmid">22238303</pub-id></element-citation></ref><ref id="B20-pathogens-09-00109"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockton</surname><given-names>J.</given-names></name><name><surname>Stephenson</surname><given-names>I.</given-names></name><name><surname>Fleming</surname><given-names>D.</given-names></name><name><surname>Zambon</surname><given-names>M.</given-names></name></person-group><article-title>Human metapneumovirus as a cause of community-acquired respiratory illness</article-title><source>Emerg. Infect. Dis.</source><year>2002</year><volume>8</volume><fpage>897</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.3201/eid0809.020084</pub-id><pub-id pub-id-type="pmid">12194763</pub-id></element-citation></ref><ref id="B21-pathogens-09-00109"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peret</surname><given-names>T.C.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Couillard</surname><given-names>M.</given-names></name><name><surname>Humphrey</surname><given-names>C.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Erdman</surname><given-names>D.D.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name></person-group><article-title>Characterization of human metapneumoviruses isolated from patients in North America</article-title><source>J. Infect. Dis.</source><year>2002</year><volume>185</volume><fpage>1660</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1086/340518</pub-id><pub-id pub-id-type="pmid">12023774</pub-id></element-citation></ref><ref id="B22-pathogens-09-00109"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>M.D.</given-names></name><name><surname>Siebert</surname><given-names>D.J.</given-names></name><name><surname>Mackay</surname><given-names>I.M.</given-names></name><name><surname>Sloots</surname><given-names>T.P.</given-names></name><name><surname>Withers</surname><given-names>S.J.</given-names></name></person-group><article-title>Evidence of human metapneumovirus in Australian children</article-title><source>Med. J. Aust.</source><year>2002</year><volume>176</volume><fpage>188</fpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2002.tb04354.x</pub-id><?supplied-pmid 11913922?><pub-id pub-id-type="pmid">11913922</pub-id></element-citation></ref><ref id="B23-pathogens-09-00109"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>A.R.</given-names></name><name><surname>Erdman</surname><given-names>D.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name><name><surname>Walsh</surname><given-names>E.E.</given-names></name></person-group><article-title>Human metapneumovirus infections in young and elderly adults</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>187</volume><fpage>785</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1086/367901</pub-id><?supplied-pmid 12599052?><pub-id pub-id-type="pmid">12599052</pub-id></element-citation></ref><ref id="B24-pathogens-09-00109"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Reeves</surname><given-names>R.M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Bassat</surname><given-names>Q.</given-names></name><name><surname>Brooks</surname><given-names>W.A.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Moore</surname><given-names>D.P.</given-names></name><name><surname>Nunes</surname><given-names>M.</given-names></name><name><surname>Rath</surname><given-names>B.</given-names></name><name><surname>Campbell</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: A systematic analysis</article-title><source>Lancet Glob. Health</source><year>2019</year><volume>7</volume><fpage>e1031</fpage><lpage>e1045</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30264-5</pub-id><pub-id pub-id-type="pmid">31303294</pub-id></element-citation></ref><ref id="B25-pathogens-09-00109"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>A.K.</given-names></name><name><surname>Fowlkes</surname><given-names>A.L.</given-names></name><name><surname>Schneider</surname><given-names>E.</given-names></name><name><surname>Mutuc</surname><given-names>J.D.</given-names></name><name><surname>Armstrong</surname><given-names>G.L.</given-names></name><name><surname>Gerber</surname><given-names>S.I.</given-names></name></person-group><article-title>Human Metapneumovirus Circulation in the United States, 2008 to 2014</article-title><source>Pediatrics</source><year>2016</year><volume>137</volume><pub-id pub-id-type="doi">10.1542/peds.2015-2927</pub-id><?supplied-pmid 27244790?><pub-id pub-id-type="pmid">27244790</pub-id></element-citation></ref><ref id="B26-pathogens-09-00109"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noordeen</surname><given-names>F.</given-names></name><name><surname>Pitchai</surname><given-names>F.N.N.</given-names></name><name><surname>Kudagammana</surname><given-names>S.T.</given-names></name><name><surname>Rafeek</surname><given-names>R.A.M.</given-names></name></person-group><article-title>A mini outbreak of human metapneumovirus infection with severe acute respiratory symptoms in a selected group of children presented to a teaching hospital in Sri Lanka</article-title><source>Virusdisease</source><year>2019</year><volume>30</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1007/s13337-019-00522-9</pub-id><pub-id pub-id-type="pmid">31179371</pub-id></element-citation></ref><ref id="B27-pathogens-09-00109"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa Ramirez</surname><given-names>J.</given-names></name><name><surname>Pulido Dominguez</surname><given-names>P.</given-names></name><name><surname>Rey Benito</surname><given-names>G.</given-names></name><name><surname>Mendez Rico</surname><given-names>J.</given-names></name><name><surname>Castellanos</surname><given-names>J.</given-names></name><name><surname>Paez Martinez</surname><given-names>A.</given-names></name></person-group><article-title>Human respiratory syncytial virus and metapneumovirus in patients with acute respiratory infection in Colombia, 2000&#x02013;2011</article-title><source>Rev. Panam. Salud Publica</source><year>2014</year><volume>36</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">25345531</pub-id></element-citation></ref><ref id="B28-pathogens-09-00109"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owor</surname><given-names>B.E.</given-names></name><name><surname>Masankwa</surname><given-names>G.N.</given-names></name><name><surname>Mwango</surname><given-names>L.C.</given-names></name><name><surname>Njeru</surname><given-names>R.W.</given-names></name><name><surname>Agoti</surname><given-names>C.N.</given-names></name><name><surname>Nokes</surname><given-names>D.J.</given-names></name></person-group><article-title>Human metapneumovirus epidemiological and evolutionary patterns in Coastal Kenya, 2007&#x02013;2011</article-title><source>BMC Infect. Dis.</source><year>2016</year><volume>16</volume><elocation-id>301</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-1605-0</pub-id><pub-id pub-id-type="pmid">27316548</pub-id></element-citation></ref><ref id="B29-pathogens-09-00109"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Srivastava</surname><given-names>M.</given-names></name></person-group><article-title>Prophylactic and therapeutic approaches for human metapneumovirus</article-title><source>Virusdisease</source><year>2018</year><volume>29</volume><fpage>434</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1007/s13337-018-0498-5</pub-id><pub-id pub-id-type="pmid">30539045</pub-id></element-citation></ref><ref id="B30-pathogens-09-00109"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafagati</surname><given-names>N.</given-names></name><name><surname>Williams</surname><given-names>J.</given-names></name></person-group><article-title>Human metapneumovirus&#x02014;What we know now</article-title><source>F1000Research</source><year>2018</year><volume>7</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.12688/f1000research.12625.1</pub-id><pub-id pub-id-type="pmid">29744035</pub-id></element-citation></ref><ref id="B31-pathogens-09-00109"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebihara</surname><given-names>T.</given-names></name><name><surname>Endo</surname><given-names>R.</given-names></name><name><surname>Kikuta</surname><given-names>H.</given-names></name><name><surname>Ishiguro</surname><given-names>N.</given-names></name><name><surname>Yoshioka</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name></person-group><article-title>Seroprevalence of human metapneumovirus in Japan</article-title><source>J. Med. Virol.</source><year>2003</year><volume>70</volume><fpage>281</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1002/jmv.10391</pub-id><pub-id pub-id-type="pmid">12696118</pub-id></element-citation></ref><ref id="B32-pathogens-09-00109"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>D.G.</given-names></name><name><surname>Zakay-Rones</surname><given-names>Z.</given-names></name><name><surname>Fadeela</surname><given-names>A.</given-names></name><name><surname>Greenberg</surname><given-names>D.</given-names></name><name><surname>Dagan</surname><given-names>R.</given-names></name></person-group><article-title>High seroprevalence of human metapneumovirus among young children in Israel</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>188</volume><fpage>1865</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1086/380100</pub-id><?supplied-pmid 14673765?><pub-id pub-id-type="pmid">14673765</pub-id></element-citation></ref><ref id="B33-pathogens-09-00109"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>K.M.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Griffin</surname><given-names>M.R.</given-names></name><name><surname>Weinberg</surname><given-names>G.A.</given-names></name><name><surname>Hall</surname><given-names>C.B.</given-names></name><name><surname>Szilagyi</surname><given-names>P.G.</given-names></name><name><surname>Staat</surname><given-names>M.A.</given-names></name><name><surname>Iwane</surname><given-names>M.</given-names></name><name><surname>Prill</surname><given-names>M.M.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name><etal/></person-group><article-title>Burden of human metapneumovirus infection in young children</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1204630</pub-id><?supplied-pmid 23406028?><pub-id pub-id-type="pmid">23406028</pub-id></element-citation></ref><ref id="B34-pathogens-09-00109"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>J.</given-names></name><name><surname>Esper</surname><given-names>F.</given-names></name><name><surname>Weibel</surname><given-names>C.</given-names></name><name><surname>Kahn</surname><given-names>J.S.</given-names></name></person-group><article-title>Seroepidemiology of human metapneumovirus (HMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing HMPV fusion protein expressed in recombinant vesicular stomatitis virus</article-title><source>J. Clin. Microbiol.</source><year>2005</year><volume>43</volume><fpage>1213</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.3.1213-1219.2005</pub-id><?supplied-pmid 15750086?><pub-id pub-id-type="pmid">15750086</pub-id></element-citation></ref><ref id="B35-pathogens-09-00109"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>J.S.</given-names></name></person-group><article-title>Epidemiology of human metapneumovirus</article-title><source>Clin. Microbiol. Rev.</source><year>2006</year><volume>19</volume><fpage>546</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1128/CMR.00014-06</pub-id><?supplied-pmid 16847085?><pub-id pub-id-type="pmid">16847085</pub-id></element-citation></ref><ref id="B36-pathogens-09-00109"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schildgen</surname><given-names>V.</given-names></name><name><surname>van den Hoogen</surname><given-names>B.</given-names></name><name><surname>Fouchier</surname><given-names>R.</given-names></name><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Alvarez</surname><given-names>R.</given-names></name><name><surname>Manoha</surname><given-names>C.</given-names></name><name><surname>Williams</surname><given-names>J.</given-names></name><name><surname>Schildgen</surname><given-names>O.</given-names></name></person-group><article-title>Human Metapneumovirus: Lessons learned over the first decade</article-title><source>Clin. Microbiol. Rev.</source><year>2011</year><volume>24</volume><fpage>734</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1128/CMR.00015-11</pub-id><?supplied-pmid 21976607?><pub-id pub-id-type="pmid">21976607</pub-id></element-citation></ref><ref id="B37-pathogens-09-00109"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midgley</surname><given-names>C.M.</given-names></name><name><surname>Baber</surname><given-names>J.K.</given-names></name><name><surname>Biggs</surname><given-names>H.M.</given-names></name><name><surname>Singh</surname><given-names>T.</given-names></name><name><surname>Feist</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>T.K.</given-names></name><name><surname>Kruger</surname><given-names>K.</given-names></name><name><surname>Gerber</surname><given-names>S.I.</given-names></name><name><surname>Watson</surname><given-names>J.T.</given-names></name><name><surname>Howell</surname><given-names>M.A.</given-names></name></person-group><article-title>Notes from the Field: Severe Human Metapneumovirus Infections&#x02014;North Dakota, 2016</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2017</year><volume>66</volume><fpage>486</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6618a7</pub-id><pub-id pub-id-type="pmid">28493852</pub-id></element-citation></ref><ref id="B38-pathogens-09-00109"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>C.R.</given-names></name><name><surname>Stockmann</surname><given-names>C.</given-names></name><name><surname>Pavia</surname><given-names>A.T.</given-names></name><name><surname>Byington</surname><given-names>C.L.</given-names></name><name><surname>Blaschke</surname><given-names>A.J.</given-names></name><name><surname>Hersh</surname><given-names>A.L.</given-names></name><name><surname>Thorell</surname><given-names>E.A.</given-names></name><name><surname>Korgenski</surname><given-names>K.</given-names></name><name><surname>Daly</surname><given-names>J.</given-names></name><name><surname>Ampofo</surname><given-names>K.</given-names></name></person-group><article-title>Incidence, Morbidity, and Costs of Human Metapneumovirus Infection in Hospitalized Children</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2016</year><volume>5</volume><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1093/jpids/piv027</pub-id></element-citation></ref><ref id="B39-pathogens-09-00109"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feudtner</surname><given-names>C.</given-names></name><name><surname>Christakis</surname><given-names>D.A.</given-names></name><name><surname>Connell</surname><given-names>F.A.</given-names></name></person-group><article-title>Pediatric deaths attributable to complex chronic conditions: A population-based study of Washington State, 1980&#x02013;1997</article-title><source>Pediatrics</source><year>2000</year><volume>106</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">10888693</pub-id></element-citation></ref><ref id="B40-pathogens-09-00109"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moe</surname><given-names>N.</given-names></name><name><surname>Krokstad</surname><given-names>S.</given-names></name><name><surname>Stenseng</surname><given-names>I.H.</given-names></name><name><surname>Christensen</surname><given-names>A.</given-names></name><name><surname>Skanke</surname><given-names>L.H.</given-names></name><name><surname>Risnes</surname><given-names>K.R.</given-names></name><name><surname>Nordbo</surname><given-names>S.A.</given-names></name><name><surname>Dollner</surname><given-names>H.</given-names></name></person-group><article-title>Comparing Human Metapneumovirus and Respiratory Syncytial Virus: Viral Co-Detections, Genotypes and Risk Factors for Severe Disease</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0170200</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0170200</pub-id><pub-id pub-id-type="pmid">28095451</pub-id></element-citation></ref><ref id="B41-pathogens-09-00109"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pancham</surname><given-names>K.</given-names></name><name><surname>Sami</surname><given-names>I.</given-names></name><name><surname>Perez</surname><given-names>G.F.</given-names></name><name><surname>Huseni</surname><given-names>S.</given-names></name><name><surname>Kurdi</surname><given-names>B.</given-names></name><name><surname>Rose</surname><given-names>M.C.</given-names></name><name><surname>Rodriguez-Martinez</surname><given-names>C.E.</given-names></name><name><surname>Nino</surname><given-names>G.</given-names></name></person-group><article-title>Human Metapneumovirus Infection is Associated with Severe Respiratory Disease in Preschool Children with History of Prematurity</article-title><source>Pediatr. Neonatol.</source><year>2016</year><volume>57</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.pedneo.2015.03.008</pub-id><pub-id pub-id-type="pmid">26117550</pub-id></element-citation></ref><ref id="B42-pathogens-09-00109"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pancham</surname><given-names>K.</given-names></name><name><surname>Perez</surname><given-names>G.F.</given-names></name><name><surname>Huseni</surname><given-names>S.</given-names></name><name><surname>Jain</surname><given-names>A.</given-names></name><name><surname>Kurdi</surname><given-names>B.</given-names></name><name><surname>Rodriguez-Martinez</surname><given-names>C.E.</given-names></name><name><surname>Preciado</surname><given-names>D.</given-names></name><name><surname>Rose</surname><given-names>M.C.</given-names></name><name><surname>Nino</surname><given-names>G.</given-names></name></person-group><article-title>Premature infants have impaired airway antiviral IFNgamma responses to human metapneumovirus compared to respiratory syncytial virus</article-title><source>Pediatr. Res.</source><year>2015</year><volume>78</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/pr.2015.113</pub-id><?supplied-pmid 26086642?><pub-id pub-id-type="pmid">26086642</pub-id></element-citation></ref><ref id="B43-pathogens-09-00109"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>E.E.</given-names></name><name><surname>Peterson</surname><given-names>D.R.</given-names></name><name><surname>Falsey</surname><given-names>A.R.</given-names></name></person-group><article-title>Human metapneumovirus infections in adults: Another piece of the puzzle</article-title><source>Arch. Intern. Med.</source><year>2008</year><volume>168</volume><fpage>2489</fpage><lpage>2496</lpage><pub-id pub-id-type="doi">10.1001/archinte.168.22.2489</pub-id><?supplied-pmid 19064834?><pub-id pub-id-type="pmid">19064834</pub-id></element-citation></ref><ref id="B44-pathogens-09-00109"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>H.</given-names></name><name><surname>Iwahashi</surname><given-names>J.</given-names></name><name><surname>Kashiwagi</surname><given-names>T.</given-names></name><name><surname>Imamura</surname><given-names>Y.</given-names></name><name><surname>Hamada</surname><given-names>N.</given-names></name><name><surname>Anraku</surname><given-names>T.</given-names></name><name><surname>Ueda</surname><given-names>S.</given-names></name><name><surname>Kanda</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name></person-group><article-title>Outbreak of human metapneumovirus infection in elderly inpatients in Japan</article-title><source>J. Am. Geriatr. Soc.</source><year>2006</year><volume>54</volume><fpage>177</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.00575_10.x</pub-id><?supplied-pmid 16420227?><pub-id pub-id-type="pmid">16420227</pub-id></element-citation></ref><ref id="B45-pathogens-09-00109"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renaud</surname><given-names>C.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Seo</surname><given-names>S.</given-names></name><name><surname>Kuypers</surname><given-names>J.</given-names></name><name><surname>Cent</surname><given-names>A.</given-names></name><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Leisenring</surname><given-names>W.</given-names></name><name><surname>Boeckh</surname><given-names>M.</given-names></name><name><surname>Englund</surname><given-names>J.A.</given-names></name></person-group><article-title>Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients</article-title><source>Biol. Blood Marrow Transplant.</source><year>2013</year><volume>19</volume><fpage>1220</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2013.05.005</pub-id><?supplied-pmid 23680472?><pub-id pub-id-type="pmid">23680472</pub-id></element-citation></ref><ref id="B46-pathogens-09-00109"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonney</surname><given-names>D.</given-names></name><name><surname>Razali</surname><given-names>H.</given-names></name><name><surname>Turner</surname><given-names>A.</given-names></name><name><surname>Will</surname><given-names>A.</given-names></name></person-group><article-title>Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin</article-title><source>Br. J. Haematol.</source><year>2009</year><volume>145</volume><fpage>667</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.07654.x</pub-id><?supplied-pmid 19344395?><pub-id pub-id-type="pmid">19344395</pub-id></element-citation></ref><ref id="B47-pathogens-09-00109"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.Y.</given-names></name><name><surname>Baek</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S.O.</given-names></name><name><surname>Choi</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Woo</surname><given-names>J.H.</given-names></name><name><surname>Sung</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>M.N.</given-names></name><name><surname>Kim</surname><given-names>D.Y.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: Analytic strategy using propensity scores</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>983</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1128/AAC.01961-12</pub-id><?supplied-pmid 23229488?><pub-id pub-id-type="pmid">23229488</pub-id></element-citation></ref><ref id="B48-pathogens-09-00109"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khawaja</surname><given-names>F.</given-names></name><name><surname>Chemaly</surname><given-names>R.F.</given-names></name></person-group><article-title>Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies</article-title><source>Haematologica</source><year>2019</year><volume>104</volume><fpage>1322</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.3324/haematol.2018.215152</pub-id><pub-id pub-id-type="pmid">31221784</pub-id></element-citation></ref><ref id="B49-pathogens-09-00109"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deffrasnes</surname><given-names>C.</given-names></name><name><surname>Hamelin</surname><given-names>M.E.</given-names></name><name><surname>Prince</surname><given-names>G.A.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus</article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1128/AAC.00793-07</pub-id><pub-id pub-id-type="pmid">17967906</pub-id></element-citation></ref><ref id="B50-pathogens-09-00109"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darniot</surname><given-names>M.</given-names></name><name><surname>Schildgen</surname><given-names>V.</given-names></name><name><surname>Schildgen</surname><given-names>O.</given-names></name><name><surname>Sproat</surname><given-names>B.</given-names></name><name><surname>Kleines</surname><given-names>M.</given-names></name><name><surname>Ditt</surname><given-names>V.</given-names></name><name><surname>Pitoiset</surname><given-names>C.</given-names></name><name><surname>Pothier</surname><given-names>P.</given-names></name><name><surname>Manoha</surname><given-names>C.</given-names></name></person-group><article-title>RNA interference in vitro and in vivo using DsiRNA targeting the nucleocapsid N mRNA of human metapneumovirus</article-title><source>Antivir. Res.</source><year>2012</year><volume>93</volume><fpage>364</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.01.004</pub-id><pub-id pub-id-type="pmid">22285728</pub-id></element-citation></ref><ref id="B51-pathogens-09-00109"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitschinsk</surname><given-names>K.M.</given-names></name><name><surname>Clarke</surname><given-names>D.T.</given-names></name><name><surname>Idris</surname><given-names>A.</given-names></name><name><surname>McMillan</surname><given-names>N.A.</given-names></name></person-group><article-title>RNAi Targeting of Human Metapneumovirus P and N Genes Inhibits Viral Growth</article-title><source>Intervirology</source><year>2018</year><volume>61</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1159/000491927</pub-id><pub-id pub-id-type="pmid">30145592</pub-id></element-citation></ref><ref id="B52-pathogens-09-00109"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>J.V.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Cseke</surname><given-names>G.</given-names></name><name><surname>Wright</surname><given-names>D.W.</given-names></name><name><surname>Keefer</surname><given-names>C.J.</given-names></name><name><surname>Tollefson</surname><given-names>S.J.</given-names></name><name><surname>Hessell</surname><given-names>A.</given-names></name><name><surname>Podsiad</surname><given-names>A.</given-names></name><name><surname>Shepherd</surname><given-names>B.E.</given-names></name><name><surname>Sanna</surname><given-names>P.P.</given-names></name><etal/></person-group><article-title>A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>8315</fpage><lpage>8324</lpage><pub-id pub-id-type="doi">10.1128/JVI.00106-07</pub-id><?supplied-pmid 17522220?><pub-id pub-id-type="pmid">17522220</pub-id></element-citation></ref><ref id="B53-pathogens-09-00109"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>E.J.</given-names></name><name><surname>Carosone-Link</surname><given-names>P.</given-names></name><name><surname>Yogev</surname><given-names>R.</given-names></name><name><surname>Yi</surname><given-names>J.</given-names></name><name><surname>Simoes</surname><given-names>E.A.F.</given-names></name></person-group><article-title>Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis</article-title><source>Pediatr. Infect. Dis. J.</source><year>2017</year><volume>36</volume><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001533</pub-id><?supplied-pmid 28709160?><pub-id pub-id-type="pmid">28709160</pub-id></element-citation></ref><ref id="B54-pathogens-09-00109"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochizuki</surname><given-names>H.</given-names></name><name><surname>Kusuda</surname><given-names>S.</given-names></name><name><surname>Okada</surname><given-names>K.</given-names></name><name><surname>Yoshihara</surname><given-names>S.</given-names></name><name><surname>Furuya</surname><given-names>H.</given-names></name><name><surname>Simoes</surname><given-names>E.A.F.</given-names></name></person-group><article-title>Scientific Committee for Elucidation of Infantile, A. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2017</year><volume>196</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1164/rccm.201609-1812OC</pub-id><?supplied-pmid 28152315?><pub-id pub-id-type="pmid">28152315</pub-id></element-citation></ref><ref id="B55-pathogens-09-00109"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helmink</surname><given-names>B.J.</given-names></name><name><surname>Ragsdale</surname><given-names>C.E.</given-names></name><name><surname>Peterson</surname><given-names>E.J.</given-names></name><name><surname>Merkel</surname><given-names>K.G.</given-names></name></person-group><article-title>Comparison of Intravenous Palivizumab and Standard of Care for Treatment of Respiratory Syncytial Virus Infection in Mechanically Ventilated Pediatric Patients</article-title><source>J. Pediatr. Pharmacol. Ther.</source><year>2016</year><volume>21</volume><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.5863/1551-6776-21.2.146</pub-id><?supplied-pmid 27199622?><pub-id pub-id-type="pmid">27199622</pub-id></element-citation></ref><ref id="B56-pathogens-09-00109"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>J.C.</given-names></name><name><surname>Tollefson</surname><given-names>S.J.</given-names></name><name><surname>Weaver</surname><given-names>D.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name></person-group><article-title>A medium-throughput screen for inhibitors of human metapneumovirus</article-title><source>Antivir. Chem. Chemother.</source><year>2019</year><volume>27</volume><pub-id pub-id-type="doi">10.1177/2040206619830197</pub-id><?supplied-pmid 30759993?><pub-id pub-id-type="pmid">30759993</pub-id></element-citation></ref><ref id="B57-pathogens-09-00109"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Lattmann</surname><given-names>S.</given-names></name><name><surname>El Sahili</surname><given-names>A.</given-names></name><name><surname>Yeo</surname><given-names>T.H.</given-names></name><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Cressey</surname><given-names>T.</given-names></name><name><surname>Ludeke</surname><given-names>B.</given-names></name><name><surname>Noton</surname><given-names>S.</given-names></name><name><surname>Kalocsay</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Structure of the human metapneumovirus polymerase phosphoprotein complex</article-title><source>Nature</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s41586-019-1759-1</pub-id><?supplied-pmid 31698413?><pub-id pub-id-type="pmid">31698413</pub-id></element-citation></ref><ref id="B58-pathogens-09-00109"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>J.</given-names></name><name><surname>Pizzorno</surname><given-names>A.</given-names></name><name><surname>Cavanagh</surname><given-names>M.H.</given-names></name><name><surname>Padey</surname><given-names>B.</given-names></name><name><surname>Nicolas de Lamballerie</surname><given-names>C.</given-names></name><name><surname>Uyar</surname><given-names>O.</given-names></name><name><surname>Venable</surname><given-names>M.C.</given-names></name><name><surname>Carbonneau</surname><given-names>J.</given-names></name><name><surname>Traversier</surname><given-names>A.</given-names></name><name><surname>Julien</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>164</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7040164</pub-id></element-citation></ref><ref id="B59-pathogens-09-00109"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>R.S.</given-names></name><name><surname>Mahmood</surname><given-names>K.</given-names></name><name><surname>Macphail</surname><given-names>M.</given-names></name><name><surname>Guzzetta</surname><given-names>J.M.</given-names></name><name><surname>Haller</surname><given-names>A.A.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Kaur</surname><given-names>J.</given-names></name><name><surname>Lawlor</surname><given-names>H.A.</given-names></name><name><surname>Stillman</surname><given-names>E.A.</given-names></name><name><surname>Schickli</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (HMPV) fusion protein elicits protective immunity in African green monkeys</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1657</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.10.009</pub-id><pub-id pub-id-type="pmid">15705469</pub-id></element-citation></ref><ref id="B60-pathogens-09-00109"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>J.T.</given-names></name><name><surname>Pickens</surname><given-names>J.A.</given-names></name><name><surname>Schuster</surname><given-names>J.E.</given-names></name><name><surname>Johnson</surname><given-names>M.</given-names></name><name><surname>Tollefson</surname><given-names>S.J.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name><name><surname>Davis</surname><given-names>N.L.</given-names></name><name><surname>Johnston</surname><given-names>R.E.</given-names></name><name><surname>Schultz-Darken</surname><given-names>N.</given-names></name><name><surname>Slaughter</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>950</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.12.045</pub-id><pub-id pub-id-type="pmid">26772634</pub-id></element-citation></ref><ref id="B61-pathogens-09-00109"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>H.</given-names></name><name><surname>Tollefson</surname><given-names>S.J.</given-names></name><name><surname>Podsiad</surname><given-names>A.B.</given-names></name><name><surname>Shepherd</surname><given-names>B.E.</given-names></name><name><surname>Polosukhin</surname><given-names>V.V.</given-names></name><name><surname>Johnston</surname><given-names>R.E.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name><name><surname>Crowe</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>11410</fpage><lpage>11418</lpage><pub-id pub-id-type="doi">10.1128/JVI.01688-08</pub-id><pub-id pub-id-type="pmid">18786987</pub-id></element-citation></ref><ref id="B62-pathogens-09-00109"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jares Baglivo</surname><given-names>S.</given-names></name><name><surname>Polack</surname><given-names>F.P.</given-names></name></person-group><article-title>The long road to protect infants against severe RSV lower respiratory tract illness</article-title><source>F1000Research</source><year>2019</year><volume>8</volume><pub-id pub-id-type="doi">10.12688/f1000research.18749.1</pub-id><?supplied-pmid 31105933?><pub-id pub-id-type="pmid">31105933</pub-id></element-citation></ref><ref id="B63-pathogens-09-00109"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skiadopoulos</surname><given-names>M.H.</given-names></name><name><surname>Biacchesi</surname><given-names>S.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Amaro-Carambot</surname><given-names>E.</given-names></name><name><surname>Surman</surname><given-names>S.R.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name></person-group><article-title>Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity</article-title><source>Virology</source><year>2006</year><volume>345</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.10.016</pub-id><?supplied-pmid 16300813?><pub-id pub-id-type="pmid">16300813</pub-id></element-citation></ref><ref id="B64-pathogens-09-00109"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryder</surname><given-names>A.B.</given-names></name><name><surname>Tollefson</surname><given-names>S.J.</given-names></name><name><surname>Podsiad</surname><given-names>A.B.</given-names></name><name><surname>Johnson</surname><given-names>J.E.</given-names></name><name><surname>Williams</surname><given-names>J.V.</given-names></name></person-group><article-title>Soluble recombinant human metapneumovirus G protein is immunogenic but not protective</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>4145</fpage><lpage>4152</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.007</pub-id><?supplied-pmid 20417260?><pub-id pub-id-type="pmid">20417260</pub-id></element-citation></ref><ref id="B65-pathogens-09-00109"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>C.J.</given-names></name><name><surname>Jones</surname><given-names>B.G.</given-names></name><name><surname>Sealy</surname><given-names>R.E.</given-names></name><name><surname>Surman</surname><given-names>S.L.</given-names></name><name><surname>Mason</surname><given-names>J.N.</given-names></name><name><surname>Hayden</surname><given-names>R.T.</given-names></name><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Takimoto</surname><given-names>T.</given-names></name><name><surname>Hurwitz</surname><given-names>J.L.</given-names></name></person-group><article-title>A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (HMPV) fusion protein protects cotton rats from HMPV challenge</article-title><source>Virology</source><year>2017</year><volume>509</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.05.021</pub-id><?supplied-pmid 28605636?><pub-id pub-id-type="pmid">28605636</pub-id></element-citation></ref><ref id="B66-pathogens-09-00109"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karron</surname><given-names>R.A.</given-names></name><name><surname>San Mateo</surname><given-names>J.</given-names></name><name><surname>Wanionek</surname><given-names>K.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group><article-title>Evaluation of a Live Attenuated Human Metapneumovirus Vaccine in Adults and Children</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2018</year><volume>7</volume><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1093/jpids/pix006</pub-id><?supplied-pmid 28444226?><pub-id pub-id-type="pmid">28444226</pub-id></element-citation></ref></ref-list></back></article>